Results: Over 7033 person-years, we observed 97 (5.6%) decompensation events (incidence rate, 13.8/1000 person-years) and 125 (7.2%) deaths (incidence rate, 17.8 events/1000 person-years). The risk of hepatic decompensation increased with cumulative mtNRTI use Conclusions: These findings suggest that cumulative mtNRTI use may increase the risk of hepatic decompensation and death in HIV/HCV coinfection. These drugs should be avoided when alternatives exist for HIV/HCV patients. 
| INTRODUCTION
Because of shared risk factors, coinfection with chronic hepatitis C virus (HCV) occurs in 10% to 30% of patients with human immunodeficiency virus (HIV) infection. [1] [2] [3] Prior studies suggest that antiretroviral therapy (ART) slows progression of HCV-associated liver fibrosis, possibly by reducing HIV-related inflammation and immune dysfunction. [4] [5] [6] [7] As a result, guidelines recommend administration of ART to all HIV-/ HCV-coinfected patients, regardless of CD4 cell count. 8 Despite the benefits of ART, 16% to 69% of HIV-/HCV-coinfected patients develop liver enzyme elevations after ART initiation, [9] [10] [11] [12] [13] [14] [15] [16] and such antiretroviral-induced liver injury may arise from different mechanisms. One important mechanism of liver injury is mitochondrial toxicity, which is caused by drug-induced depletion of mitochondrial DNA. 17 Liver injury due to mitochondrial toxicity may develop after initiation of certain antiretrovirals within the nucleoside reverse transcriptase inhibitor (NRTI) class, specifically didanosine, stavudine, zidovudine, or zalcitabine. 17 These mitochondrial toxic NRTIs (mtNRTIs) are no longer recommended as part of first-line HIV treatment regimens, but some are still used within ART regimens in resourceconstrained settings due to their low cost, or may be selected for patients with preexisting drug resistance. 8 Presently, it remains unclear if cumulative use of mtNRTIs among HIV-/HCV-coinfected patients hastens progression to hepatic decompensation, the main endpoint of chronic viral hepatitis defined by development of any clinical complication of cirrhosis, including ascites, spontaneous bacterial peritonitis, variceal hemorrhage, or hepatic encephalopathy. 18 Prolonged exposure to mtNRTIs could lead to chronic hepatic injury, which might accelerate HCV-associated liver fibrosis progression and increase risk of hepatic decompensation. Further, hepatic injury induced by these agents may persist even after they have been discontinued and affect subsequent liver function. 19 Studies that evaluate the risk of hepatic decompensation associated with cumulative use of antiretrovirals among HIV-/HCV-coinfected patients are needed to examine the hepatic safety of these drugs in this population.
Our aim was to determine if cumulative use of mtNRTIs (didanosine, stavudine, zidovudine, or zalcitabine) increased risk of hepatic decompensation among HIV-/HCV-coinfected patients compared with use of other NRTIs. We hypothesized that longer duration of use of these antiretrovirals was associated with a higher risk of decompensation in coinfected individuals.
2 | METHODS
| Study design and data source
We conducted a retrospective cohort study among ART-treated HIV-/ 
| Ascertainment of mtNRTI use
Our primary exposure was use of any mtNRTI (didanosine, stavudine, zalcitabine, and zidovudine), which was determined on a monthly basis via prescription fills. Patients were classified as exposed for any month (30-d period) covered by the fill. Exposure was captured using 2 variables: current and cumulative mtNRTI use. Over each month of
KEY POINTS
• Cumulative mitochondrial toxic nucleoside reverse transcriptase inhibitor (mtNRTI) use increases the risk of both hepatic decompensation and death in the setting of human immunodeficiency virus/chronic hepatitis C virus coinfection.
• The risk for decompensation and death increased with current and past cumulative mtNRTI exposure, suggesting that the risk of these adverse outcomes persists even after discontinuation of the drugs.
• Coinfected patients with prolonged mtNRTI exposure might benefit from closer monitoring for development of hepatic decompensation, even after these drugs' discontinuation.
• ), and potentially hepatotoxic non-antiretroviral drugs (defined below). Diabetes was defined by serum glucose ≥200 mg/dL, ICD-9 diagnosis, or antidiabetic medication use. 26, 27 Alcohol dependence/abuse 28 and injection/ noninjection drug use 28, 29 were defined by validated ICD-9 diagnoses. Use of potentially hepatotoxic non-antiretroviral medications was determined by a fill for acetaminophen (alone or in combination with an opioid), statins (pravastatin, lovastatin, simvastatin, fluvastatin, atorvastatin, cerivastatin, or rosuvastatin), duloxetine, isoniazid, metformin, thiazolidinediones (pioglitazone, rosiglitazone), or valproic acid. These drugs were selected because of their known potential for acute liver injury 30 and frequency of prescription among HIV/HCV patients. 31, 32 Baseline laboratory data collected from dates closest to but prior to start of follow-up included pre-ART HIV RNA, pre-ART CD4 count, HCV RNA, HCV genotype, hepatitis B surface antigen, serum creatinine, hemoglobin, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and platelet count. Baseline FIB-4, a noninvasive measure of advanced hepatic fibrosis, was determined by
). 33 Because liver fibrosis can progress by one stage within 4 years among ART-treated HIV-/HCV-coinfected persons, 34 we determined baseline FIB-4 scores using the component tests within a 2-year period around the start of follow-up. FIB-4 scores <1.45 were considered no/minimal fibrosis, and scores >3. prior ART use and influence selection of future ART regimens. We therefore used marginal structural models to account for time-dependent confounding.
35-37
| Derivation of patient-specific weights
We first modeled the probability of receiving an mtNRTI and the probability that a patient remained uncensored to develop patientspecific weights at baseline and over each month of follow-up. 38 Although the traditional method of modeling these probabilities is logistic regression, the validity of this method depends on this model being correctly specified. 37 To overcome this limitation, we used an alternative method, SuperLearner, which is an ensemble machinelearning method that incorporates a variety of prediction algorithms and uses cross-validation to choose an optimal prediction based on a set of different algorithms. 39, 40 SuperLearner has been shown to be more robust to deviations from parametric assumptions in observational studies. 41 The prediction algorithms incorporated included logistic regression, generalized additive models, naïve Bayes classifiers, and multivariate adaptive regression splines. 42 We used twofold cross-validation in SuperLearner to select the best algorithm or combination for prediction.
For each patient, the probability of mtNRTI treatment at each month and the probability of remaining uncensored at each month were multiplied, and the inverse of these probabilities yielded the patient-specific weights. 38 To prevent outlying data from exerting undue influence over the sample, we truncated weights at the 0.5th and 99.5th percentiles.
| Causal effect of mtNRTI use on hepatic decompensation and death
The weights were used to estimate parameters within marginal structural models. Descriptive analyses were conducted using SAS 9.4 (SAS Institute
Inc, Cary, North Carolina). Marginal structural models were fitted in R 3.1.0 using SuperLearner and geepack packages. 43 We used multiple imputation, by means of 10 imputations using all variables in Table 1 and outcomes, to assign values for missing data. 44 Results across the 10 datasets were combined to arrive at CIs that accounted for withinand across-dataset variances. 45 
| Sensitivity analyses
We conducted 3 sensitivity analyses to assess the robustness of our findings. First, we compared the impact of twofold cross-validation (used in primary analyses) versus tenfold cross-validation to reduce the likelihood for overfitting by SuperLearner.
Second, we assessed how sensitive our results were to the use of SuperLearner models to estimate patient-derived weights by substituting traditional logistic regression. We evaluated 3 methods to derive weights: (1) SuperLearner for all weights (treatment and censoring), The cohort was predominantly male and black, and 6.2% had a documented history of alcohol dependence/abuse ( Cumulative mtNRTI use was also associated with a higher risk of death. Hazard ratios of death increased with higher cumulative mtNRTI use when considered as a continuous covariate (P = .030) or categorical variable (Figure 2 ). Hazard ratios of death also increased with both current and past cumulative mtNRTI exposure (Figure 3 ).
Hazard ratios of hepatic decompensation associated with cumulative mtNRTI exposure were almost identical when using twofold and tenfold cross-validation for derivation of patient-specific weights (Appendix S5). However, the use of logistic regression to derive both treatment and censoring weights resulted in HRs that differed in magnitude from those obtained using SuperLearner to develop both treatment and censoring weights (with either twofold or tenfold cross-validation) and from those using SuperLearner with twofold cross-validation to develop treatment weights and logistic regression to derive censoring weights (Appendix S5). Similar HRs and 95% CIs were observed across different truncation points Cumulative use is the total number of months treated with an mtNRTI (as determined by prescription fills), not including the current month threefold higher odds of worsening of hepatic fibrosis. 47 Similarly, a cross-sectional analysis of 671 HIV/HCV patients in France found that a median use of didanosine of >5 months increased the odds of advanced hepatic fibrosis via transient elastography by 70%. 48 The increased risk of hepatic decompensation and death associated with increasing mtNRTI use is biologically plausible. These agents can inhibit human mitochondrial DNA polymerase gamma, which can result in depletion of mitochondrial DNA and impairment of mitochondrial functionality. 49, 50 Continued mitochondrial dysfunction can persist even after discontinuation of the offending agent and lead to oxidative damage, hepatic steatosis, hepatocellular injury, and development of hepatic fibrosis that can progress to cirrhosis. 48, 51 This study provides methodological contributions for future pharmacoepidemiological analyses evaluating the effects of cumulative exposure to antiretrovirals on health outcomes. In our primary analyses, we used SuperLearner with twofold cross-validation to model the probability of mtNRTI treatment and probability of censoring at each month of follow-up to obtain patient-specific weights. Sensitivity analyses demonstrated that we could accurately derive these weights and save computational time by using SuperLearner with twofold cross-validation to model the monthly probability of mtNRTI treatment but use logistic regression to model the monthly probability of censoring. Sensitivity analyses showed that our results are robust to the choice of truncation point. We did not have unduly large weights, so truncation did not alter the results.
Our study has several potential limitations. First, we might have underestimated the number of decompensation events since our definition did not include hepatic encephalopathy. However, outcomes
were identified using a validated definition that had a negative predictive value of >99%. 25 Further, the incidence rate of decompensation among coinfected patients in this study (13.8/1000 person-years) was similar to that reported in another cohort of coinfected patients (11.6/1,000 person-years). 6 Second, confounding by indication is a concern since ART regimen selection was by clinician choice. 52 We modeled the probability of mtNRTI treatment over each month of follow-up, but bias due to channeling may remain. 53 Given mtNRTIs' known potential for adverse effects, clinicians might have more likely prescribed these drugs to coinfected patients with less liver fibrosis. However, channeling mtNRTIs away from sicker patients would result in a lower likelihood of developing hepatic decompensation, biasing results toward the null hypothesis. Finally, our sample included mostly male US patients, and results may not be generalizable to coinfected women, FIGURE 3 Forest plots of hazard ratios of hepatic decompensation ( Figure 3A ) and death ( Figure 3B ) associated with current and past cumulative mitochondrial toxic nucleoside reverse transcriptase inhibitor (mtNRTI) use compared to no (current or past) mtNRTI use. Current mtNRTI use refers to treatment regimens where, once mtNRTI use began, it did not stop. Past mtNRTI use refers to treatment regimens that involve past, but not current, mtNRTI use. A, Hepatic decompensation. B, Death. Abbreviations: CI, confidence interval; mtNRTI, mitochondrial toxic nucleoside reverse transcriptase inhibitor patients outside the United States, or those treated according to more recent management guidelines. Our study also excluded patients who received antiviral treatment for chronic HCV prior to the start of followup and censored observation time at initiation of HCV therapy. Thus, this study cannot inform the impact that successful HCV therapy might have on the risk of decompensation associated with mtNRTI use.
In conclusion, cumulative mtNRTI use was associated with an increased risk of hepatic decompensation and death among HIV-/ HCV-coinfected patients. These agents should be avoided in HIV/ HCV patients when other options are available.
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